Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.
Kotagiri S, Blazanin N, Xi Y, Han Y, Qudratullah M, Liang X, Wang Y, Pandey P, Mazhar H, Lam TN, Singh AK, Wang J, Lissanu Y.
Kotagiri S, et al. Among authors: han y.
Cell Chem Biol. 2024 Oct 1:S2451-9456(24)00396-9. doi: 10.1016/j.chembiol.2024.09.004. Online ahead of print.
Cell Chem Biol. 2024.
PMID: 39378885
Free article.